跳至主要内容
临床试验/NCT03601949
NCT03601949已完成不适用

A Prospective, Multi-center, Randomized, Assessor Blind, Controlled Study Comparing Lateral Branch Cooled Radiofrequency Denervation to Conservative Therapy as Treatment for Sacroiliac Joint Pain in a Military and Civilian Population

Avanos Medical30 个研究点 分布在 1 个国家目标入组 210 人开始时间: 2018年6月29日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
210
试验地点
30
主要终点
Change in average daily pain Numeric Rating Scale (NRS) score

研究概览

简要总结

This is a prospective, randomized, controlled, multi-center clinical study. Approximately 208 subjects will be enrolled at approximately 12-15 active duty military, veterans' care, and civilian sites. Eligible subjects will be randomized in 1:1 ratio to receive either Sacroiliac denervation using CRF (treatment group) or standard medical management ("SMM," control group).

详细描述

This study will be a 12-month prospective, randomized, controlled, prospective, open-label, multi-center clinical study. Adult subjects over the age of 21 with diagnosed chronic intractable sacroiliac joint pain (≥ 3 months), who have been previously unresponsive to conservative therapy and who meet the selection criteria are eligible to participate in this study. Approximately 208 subjects will be enrolled at up to 15 sites in a 1:1 randomization ratio to receive either denervation using the SInergy System (cooled radiofrequency (CRF), treatment group) or standard medical management (SMM, control group). Follow-up will be conducted for a total of 12 months post-Coolief (cooled radiofrequency ablation) procedure, with the primary endpoint being completed at month 3. The control arm will utilize physician prescribed standard medical management (SMM). For this protocol, this includes, but is not limited to, medications, physical therapy, lifestyle changes, acupuncture, yoga, chiropractic, and therapeutic injections. An optional crossover-to-treatment design was adopted for subjects randomized to standard medical management after their 3-month visit, because it would be considered unethical to withhold treatment that could potentially offer pain relief to those subjects undergoing standard medical management who continue to suffer from pain.

Eligibility includes BOTH of the following:

  • 50% pain relief lasting for the expected duration of anesthetic or medication from a therapeutic or diagnostic sacroiliac joint injection; AND

  • 50% pain relief lasting for the expected duration of anesthetic from a standardized set of lateral branch blocks, with total volume of no more than 1 milliliter (ml) of 0.5% Bupivacaine, Ropivacaine (or similar). Ideally, 0.5 ml will be utilized at L5 and the remaining 0.5 ml should be divided in at least two locations along the foramen line

After the CRF treatment, the CRF treatment group subjects will visit the blinded assessor for follow up at 1, 3, 6, 9, and 12 months. At the month 3 visit (three months post-randomization), subjects initially randomized to the conservative therapy group will be assessed to determine eligibility to receive CRF treatment.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

盲法说明

The study is an assessor blinded trial and deliberate action will be needed to ensure the blind remains. This begins with randomization procedures and carries through the follow up visits. It is suggested that all follow up visit documentation not contain the visit number, but instead utilize visit dates to track progress.

入排标准

年龄范围
21 Years 至 110 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age greater than or equal to 21 years.
  • Able to understand the informed consent, and able to complete outcome measures.
  • Sacroiliac joint (SIJ) pain that is refractory to standard of care treatments such as non-steroidal anti-inflammatory drugs (NSAIDS), physical therapy, etc.
  • At least one positive SIJ pain provocation test (Distraction, Gaenslen's, FABER, Sacral Sulcus tenderness, thigh thrust, compression or sacral thrust).
  • Back pain is predominantly below the lumbar (L) 5 vertebrae.
  • Chronic low back pain lasting for longer than three months.
  • Greater than 50% pain relief lasting for the expected duration of anesthetic or medication from a therapeutic or diagnostic SIJ injection.
  • Greater than 50% pain relief lasting the duration of anesthetic from lateral branch block (done on different days than SIJ injection).
  • Stabilized on pain medication regimen for > 2 months, as defined by a < 10% change in dosage.
  • Numeric rating scale indicating an average pain score of > 4 over the last seven days. (returned to pre-lateral branch block baseline pain).
  • All other possible sources of low back pain have been ruled out as the primary pain generator, including, but not limited to: suspected advanced degenerative joint disease, the intervertebral discs, bone fracture, the zygapophyseal joints, the hip joint, symptomatic spondylolisthesis, tumor, and other regional soft tissue structures (this is done by physical exam, medical history, and magnetic resonance imaging/computed tomography/X-ray, as required).
  • Willing to utilize double barrier contraceptive method, if of child-bearing potential.
  • Willingness to provide informed consent and to comply with the requirements of this protocol for the full duration of the study.
  • Physician believes ablation of the SIJ is an appropriate treatment for the patient.

排除标准

  • Poorly controlled severe psychiatric illness or ongoing psychological barriers to recovery, as determined by the treating physician.
  • Spinal pathology that may impede recovery such as spina bifida occulta, grade II or higher spondylolisthesis at vertebrae L5/sacroiliac (S) 1, or scoliosis.
  • Symptomatic moderate or severe foraminal or central canal stenosis.
  • Systemic infection or localized infection at anticipated introducer entry site.
  • Uncontrolled immunosuppression (e.g., acquired immune deficiency syndrome (AIDS), cancer, diabetes, etc.)
  • Chronic severe conditions such as rheumatoid/inflammatory arthritis.
  • Pregnancy or recent delivery (within three months).
  • Active radiculopathy pain from lumbar spine.
  • Active hip pathology.
  • Major surgery within three months prior to signing informed consent.
  • Prior radiofrequency denervation of the lateral sacral nerves.
  • Ongoing/unresolved worker's compensation, injury litigation, military medical board, or disability remuneration claims.
  • Allergy to injected substances or medications used in procedure.
  • Body mass index (BMI) > 40 kilograms/meter (squared).
  • Current prescribed opioid medications equivalent to 90 mg of morphine per 24 hours or greater.
  • Subject is currently implanted with pacemaker, stimulator, or defibrillator.
  • Participation in another clinical trial/investigation that could interfere with this trial 30 days prior to signing informed consent.
  • Subject is unwilling or unable to comply with the protocol requirements.

结局指标

主要结局

Change in average daily pain Numeric Rating Scale (NRS) score

时间窗: Baseline and 3 months

Numeric Rating Scale (NRS) - score range = 0 - 10. "0" corresponds to "no pain" and "10" indicates "worst pain imaginable". The means of these scores and their respective standard deviations are reported for each study group.

次要结局

  • Mean change in score of Short Form 36-Physical Functioning (SF36-PF)(Baseline and 3 months)
  • The proportion of subjects with at least a 2 points decrease or 30% drop in average daily pain related NRS score AND a rating of at least 5 on the Patient Global Impression of Change (PGIC)(Baseline and 3 months)
  • Mean change in score of Patient Global Impression of Change (PGIC)(Baseline and 3 months)
  • Mean change in score of Oswestry Disability Index (ODI)(Baseline and 3 months)
  • Mean change in score of EuroQuol (EQ) 5D-5L(Baseline and 3 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (30)

Loading locations...

相似试验